13 completed, 2 active not recruiting, 1 recruiting, 1 terminated. 17 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 17 | Completed 13, Active not recruiting 2, Recruiting 1, Terminated 1 |
| Phase 2 | 1 | Completed 1 |
Follow Peanut Allergy: new trials by email Literature Review of Peanut Allergy trials Research Report on Peanut Allergy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A 52-week Study of Remibrutinib in IgE-mediated Food Allergy Remibrutinib, Placebo - IgE-Mediated Food Allergy, Peanut Allergy | Phase 3 | Recruiting | Novartis Pharmaceuticals | 576 | 2026-08-27 | 2026-10-13 |
| Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers) DBV712 250 mcg, Placebo - Allergy, Peanut Allergy | Phase 3 | Active not recruiting | DBV Technologies | 480 | 2025-06-24 | 2026-07-22 |
| Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Participants Omalizumab, Placebo for Omalizumab, Multi-Allergen Oral Immunotherapy - Peanut Allergy, Multi-food Allergy | Phase 3 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 458 | 2019-07-22 | 2026-09-22 |
| Peanut Oral Immunotherapy Study of Early Intervention for Desensitization AR101 powder provided in capsules & sachets, Placebo powder provided in capsules & sachets - Peanut Allergy | Phase 3 | Completed | Aimmune Therapeutics, Inc. | 146 | 2018-12-27 | 2023-03-02 |
| Follow-up of the EPITOPE Study to Evaluate Long-term Efficacy and Safety of DBV712 in Young Children DBV712 250 mcg - Peanut Allergy | Phase 3 | Completed | DBV Technologies | 304 | 2018-12-06 | 2026-10-28 |
| Real World, Open Label, QOL Assessment of Peanut Immunotherapy AR101 in Children and Adolescents AR101 - Peanut Allergy | Phase 3 | Terminated | Aimmune Therapeutics, Inc. | 1 | 2018-10-24 | 2021-07-13 |
| Longer-term Study of AR101 in Subjects Who Participated in a Prior AR101 Study (ARC008) AR101 - Peanut Allergy | Phase 3 | Completed | Aimmune Therapeutics, Inc. | 911 | 2017-11-02 | 2024-12-19 |
| AR101 Real-World Open-Label Extension Study AR101 - Peanut Allergy | Phase 3 | Completed | Aimmune Therapeutics, Inc. | 243 | 2017-10-18 | 2021-11-02 |
| Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Young Children 1-3 Years of Age Part A Viaskin Peanut 250 mcg, Part A Viaskin Peanut 100 mcg, Part A Placebo - Peanut Allergy | Phase 3 | Completed | DBV Technologies | 414 | 2017-07-31 | 2024-12-16 |
| ARTEMIS Peanut Allergy In Children AR101 powder provided in capsules & sachets, Placebo powder provided in capsules & sachets - Peanut Allergy | Phase 3 | Completed | Aimmune Therapeutics, Inc. | 175 | 2017-06-12 | 2021-08-03 |
| Real-World AR101 Market-Supporting Experience Study in Peanut-Allergic Children (RAMSES) AR101, Placebo - Peanut Allergy | Phase 3 | Completed | Aimmune Therapeutics, Inc. | 506 | 2017-05-08 | 2021-11-02 |
| Follow-up of the PEPITES Study to Evaluate Long-term Efficacy and Safety of Viaskin Peanut in Children Viaskin Peanut 250µg - Peanut Allergy | Phase 3 | Active not recruiting | DBV Technologies | 300 | 2017-01-23 | 2020-12-02 |
| PALISADE Follow-on Study (ARC004) AR101 - Peanut Allergy | Phase 3 | Completed | Aimmune Therapeutics, Inc. | 388 | 2016-12-29 | 2022-03-17 |
| Safety Study of Viaskin Peanut to Treat Peanut Allergy Viaskin Peanut 250 µg, Placebo - Peanut Allergy | Phase 3 | Completed | DBV Technologies | 393 | 2016-10-25 | 2026-10-08 |
| Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE) AR101 powder provided in capsules & sachets, Placebo powder provided in capsules & sachets - Peanut Allergy | Phase 3 | Completed | Aimmune Therapeutics, Inc. | 555 | 2015-12-22 | 2022-03-17 |
| Efficacy and Safety of Viaskin Peanut in Children With Immunoglobulin E (IgE)-Mediated Peanut Allergy Viaskin Peanut 250mcg, Placebo - Peanut Allergy | Phase 3 | Completed | DBV Technologies | 500 | 2015-12-01 | 2025-06-18 |
| Peanut Oral Induction Tolerance in Peanut's Allergic Teenagers arachid, Placebo - Peanut Allergy | Phase 2 / Phase 3 | Completed | University Hospital, Clermont-Ferrand | 60 | 2013-07-18 | 2026-08-03 |
Peanut Hypersensitivity (17) · Hypersensitivity (8) · Food Hypersensitivity (4) · Egg Hypersensitivity (1) · Milk Hypersensitivity (1) · Nut and Peanut Hypersensitivity (1) · Severe combined immunodeficiency with sensitivity to ionizing radiation (1)
Hypersensitivity, Immediate (17) · Immune System Diseases (17) · Nut and Peanut Hypersensitivity (16) · Food Hypersensitivity (13) · Hypersensitivity (9)
Capsules (3) · Omalizumab (1) · remibrutinib (1)
Aimmune Therapeutics, Inc. (8) · DBV Technologies (6) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Novartis Pharmaceuticals (1) · University Hospital, Clermont-Ferrand (1)
United States (14) · Canada (10) · Germany (8) · Ireland (8) · United Kingdom (7) · France (6) · Spain (6) · Netherlands (5) · Australia (4) · Italy (4) · Sweden (4) · Denmark (1)
David M Fleischer, MD (1) · Jen Garcia (1) · Robert A. Wood, MD (1) · Sharon Chinthrajah, MD (1)
PMID 34389504, PMID 34320250, PMID 36915184, PMID 37163622, PMID 25925398, PMID 30449234, PMID 30794314, PMID 31442495, PMID 32502548, PMID 32702315, PMID 33259921, PMID 38282192, PMID 38320526, PMID 38407394, PMID 39956162, PMID 40023371, PMID 40204253, PMID 41651410
2018 (1)